Reports
Generics reduce costs and increase access
Generics reduce costs for both patients and payers and increase patient’s access to medicines, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).
Generics savings continue to climb in the US
Generics manufacturers have joined to celebrate the latest data from the Generic Drug Savings in the US report. According to the report, the US healthcare system saved a record US$254 billion in 2014 from generics, or US$1.68 trillion between 2005 and 2014.
Pivotal clinical trials for trastuzumab biosimilars
Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.
Pivotal clinical trials for rituximab biosimilars
Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.
German physicians not pressured to switch to biosimilar infliximab
Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.
Pivotal clinical trials for bevacizumab biosimilars
Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.
Generics use in Italy could save Euros 1.4 billion per year
A report published by Italian generics association Assogenericion on 5 May 2015 points to the fact that generics are crucial in the containment of pharmaceutical expenditure in Italy.
Clinical programmes for oncology biosimilars
Biosimilars for oncology drugs are currently under development. These include biosimilars of blockbusters such as Roche’s Avastin (bevacizumab), MabThera/Rituxan (rituximab) and Herceptin (trastuzumab).
Doctors’ survey reveals lack of confidence in biosimilars
Online physician’s platform and community QuantiaMD survey of 300 primary care physicians and specialists in the US has found a lack of confidence concerning biosimilars.
Clinical programmes for anti-TNF biosimilars
Biosimilars for anti-tumour necrosis factor (anti-TNF) drugs are currently under development. These include biosimilars of blockbusters such as AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Remicade (infliximab).
